Features
Nasus Pharma Is Targeting the Next Evolution of Emergency Allergy Treatment - And Wall Street Is Starting to Notice
Nasus Pharma is betting it can reinvent emergency allergy treatment with a needle-free epinephrine nasal spray - and after strong Phase II data and a new $19 Zacks price target, Wall Street may be starting to pay attention | NYSE: NSRX*